Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Tenofovir alafenamide fumarate (TAF) co-formulated with elvitegravir (EVG, E), cobicistat (C) and emtricitabine (F), a recommended antiretroviral regimen, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF) as well as neurocognitive (NC) performance change in participants switching from E/C/F/TDF to E/C/F/TAF. This was a 24-week, single-arm, open-label study in treatment-experienced adults living with HIV. Nine participants switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300 mg once daily) to E/C/F/TAF (150/150/200/10 mg once daily) at week 12. CSF and total plasma concentrations of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measured at baseline and week 24. NC performance was estimated by the Montreal Cognitive Assessment. EVG concentrations in CSF and the CSF:plasma ratio (CPR) remained stable (p=0.203) over time. Following the switch, TFV concentrations in CSF and plasma declined (p=0.004), although the TFV CPR increased (p=0.004). At week 24, median TAF plasma concentration was 11.05 ng/mL (2 hours post-dose, range 2.84-147.1 ng/ml) but was below assay sensitivity 6 hours after dosing. TAF was below assay sensitivity in all CSF specimens. HIV RNA were ≤40 copies/mL in all CSF and plasma specimens. Three participants (33%) had NC impairment at baseline and two (22%) remained impaired at week 24. Switch to E/C/F/TAF was associated with reductions in TFV concentrations in CSF but stable EVG concentrations that exceeded the IC50 for wild-type HIV, suggesting that EVG achieves therapeutic concentrations in the central nervous system. No virologic failure or significant NC changes were detected following the switch.Clinical Trials Rwegistration: NCT02251236.